ReviewClinical and vaccine immunology : CVI2011
Seroprevalence to influenza A(H1N1) 2009 virus--where are we?
Review in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries.Influenza and other respiratory viruses · 2013Pooled it
- Landscape of coordinated immune responses to H1N1 challenge in humans.The Journal of clinical investigation · 2020Trial
- Inferring influenza infection attack rate from seroprevalence data.PLoS pathogens · 2014Trial
- Assembling unregulated DNA segments bypasses synthesis screening: regulate fragments as select agents.Nature communications · 2026Article
- Mathematical modelling for vaccine efficacy trials during the future epidemics of emerging respiratory infections.Human vaccines & immunotherapeutics · 2025Article
- Neuraminidase Antibody Response to Homologous and Drifted Influenza A Viruses After Immunization with Seasonal Influenza Vaccines.Vaccines · 2024Article
- Influenza Vaccine Effectiveness Among Children: 2011-2020.Pediatrics · 2023Article
- Human Immunity and Susceptibility to Influenza A(H3) Viruses of Avian, Equine, and Swine Origin.Emerging infectious diseases · 2023Article
- Determining Existing Human Population Immunity as Part of Assessing Influenza Pandemic Risk.Emerging infectious diseases · 2022Article
- Article
- Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age GroupEmerging infectious diseases · 2020Article
- Identification of novel influenza A virus exposures by an improved high-throughput multiplex MAGPIX platform and serum adsorption.Influenza and other respiratory viruses · 2020Article
- Seroprevalence of influenza A H1N1 (swine) infection in the human population in a cantonment.Medical journal, Armed Forces India · 2019Article
- Population Serologic Immunity to Human and Avian H2N2 Viruses in the United States and Hong Kong for Pandemic Risk Assessment.The Journal of infectious diseases · 2018Article
- H7N9 Avian Influenza Virus Is Efficiently Transmissible and Induces an Antibody Response in Chickens.Frontiers in immunology · 2018Article
- Detecting a Surprisingly Low Transmission Distance in the Early Phase of the 2009 Influenza Pandemic.Scientific reports · 2017Article
- Infection with influenza A(H1N1)pdm09 during the first wave of the 2009 pandemic: Evidence from a longitudinal seroepidemiologic study in Dhaka, Bangladesh.Influenza and other respiratory viruses · 2017Article
- Structure of general-population antibody titer distributions to influenza A virus.Scientific reports · 2017Article
- Evaluation of multiplex assay platforms for detection of influenza hemagglutinin subtype specific antibody responses.Journal of virological methods · 2017Article
- Novel multiplex assay platforms to detect influenza A hemagglutinin subtype-specific antibody responses for high-throughput and in-field applications.Influenza and other respiratory viruses · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-specific seroprevalences for influenza virus make important contributions to estimating the burden of infection and determining the vulnerable populations. It is especially difficult to know the true clinical attack rates of the 2009 influenza A(H1N1) pandemic; however, we can estimate infection rates through analyses of seroprevalences based on national studies from different continents and countries with different demographics. After the 2009 influenza A(H1N1) pandemic, seroprevalence studies found 5 to 60% of populations across different continents and age groups having antibodies against the A(H1N1) 2009 virus. The seropositivity was highest in children and teenagers (20 to 60%) as well as in the elderly older than 80 years (20 to 40%). Preexisting cross-reactive antibodies against the virus were present mostly in sera of older people (born before 1950) who could have encountered viruses descended from the 1918 pandemic viruses. Experience with the 2009 pandemic indicates how essential early and timely serology data against the emerging virus can be for informing decisions on use of antivirals and vaccination campaigns, especially in regard to risk groups. The objectives of this review were to summarize the current data available on seroprevalence before and after the 2009 influenza A(H1N1) pandemic and the lessons learned for future pandemic preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.